EUVIMEDEUVIMED entdecken
Systematische Übersicht

Assessing Digital Health Technologies for Outcome Measurement in Parkinson's Disease Drug Trials: A Systematic Review

Bewertung digitaler Gesundheitstechnologien zur Ergebnismessung in Arzneimittelstudien bei Parkinson: systematische Übersichtsarbeit

Sasivimol Virameteekul iD, Chaewon Shin iD, Siegfried S Hirczy iD, Harini Sarva, Serene S Paul, Walter Maetzler, Anat Mirelman iD, Ruth B Schneider iD, Jeffrey M Hausdorff, Joaquin A Vizcarra iD, Jochen Klucken, Mariana H G Monje iD und 15 weitere

Movement Disorders · 2026-01 · 41 (1) · 40-62

DOI: 10.1002/mds.70097 ↗

Auf einen Blick

Die Übersichtsarbeit zu 42 Studien zeigt, dass digitale Gesundheitstechnologien in Parkinson-Studien motorische Symptome objektiv erfassen können. Nur Opal erreichte Level 1a Evidenz.

Fragestellung

Welche Rolle haben digitale Gesundheitstechnologien als Outcome-Tools in pharmakologischen Studien bei Parkinson?

Methode

Systematische Suche in MEDLINE und Embase nach PRISMA bis 31. August 2025; eingeschlossen waren RCTs, Open-Label-, Crossover- und Beobachtungsstudien.

Ergebnisse

42 Studien mit 26 DHTs. 11 tragbare Sensoren und 15 nicht tragbare Systeme. 15 Studien waren hoch, 14 moderat und 13 niedrig in der Qualität; nur Opal erreichte Level 1a Evidenz.

Einschränkungen

Nur Studien ab 10 Teilnehmenden; größere Standardisierung und regulatorische Angleichung werden laut Autor:innen benötigt.

Schlussfolgerung der Autor:innen

DHTs sind nützliche Werkzeuge für die objektive Erfassung in Parkinson-Studien, ihr breiter Einsatz erfordert jedoch mehr Standardisierung und regulatorische Angleichung.

Kernaussagen

  • 42 Studien und 26 verschiedene DHTs
  • Nur Opal erreichte Level 1a Evidenz
  • DHTs wurden in überwachten und nicht überwachten Settings eingesetzt

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Systematische Übersicht in der Zeitschrift Movement Disorders, online erschienen am 01.11.2025. Verfasst von Sasivimol Virameteekul und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, …. Hauptthemen laut MEDLINE: Parkinson Disease, Outcome Assessment, Health Care, Wearable Electronic Devices, Antiparkinson Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 83 Literaturangaben. Gefördert von: NICHD NIH HHS.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Traditional clinical assessments in Parkinson's disease (PD) trials are limited by subjectivity and inter‐rater variability. Digital health technologies (DHT) offer an objective continuous assessment of motor symptoms and are increasingly used in clinical research. This review evaluated the role of DHTs as outcome tools in pharmacological trials for PD. A systematic search of MEDLINE and Embase was conducted according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses) guidelines, covering studies up to August 31, 2025. Eligible studies included randomized controlled trials, open‐label or crossover designs, and observational studies using DHTs to assess motor outcome variables in PD. Studies focusing only on technology development or with fewer than 10 participants were excluded. Data extracted included study design, DHT type, assessment setting, and motor parameters measured. Study quality was appraised using an eight‐criterion tool, and level of evidence was rated using the Oxford Centre for Evidence‐Based Medicine framework. A total of 42 studies were included, covering 26 distinct DHTs. These comprised 11 wearable sensors and 15 nonwearable systems such as motion capture platforms and force‐sensing assessments. DHTs were used to measure bradykinesia, tremor, gait, balance, and nocturnal motor symptoms in both supervised and unsupervised settings. Fifteen studies were rated as high quality, 14 moderate, and 13 low. Among currently available tools, only Opal reached the threshold of Level 1a evidence. Other validated tools included the Parkinson's Kinetigraph, Actiwatch, and Roche PD Mobile Application (Level 1b). DHTs offer valuable tools for objective assessment in PD trials, though broader adoption requires greater standardization and regulatory alignment. © 2025 International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseOutcome Assessment, Health CareWearable Electronic DevicesAntiparkinson AgentsHumansDigital Health

Stichwörter der Autor:innen

Parkinson's diseaseclinical trialsdigital health technologyoutcome measurementwearable sensors

Substanzen

Antiparkinson Agents

Autor:innen und Institutionen

  • Department of Biochemistry, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
  • Department of Neurology, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea.
  • Department of Neurology, University of Texas Southwestern, Dallas, Texas, USA.
  • Department of Neurology, Parkinson's Disease and Movement Disorders Institute, Weill Cornell Medicine, New York, New York, USA.
  • Sydney School of Health Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Department of Neurology, Kiel University, Kiel, Germany.

ORCID-Profile: Sasivimol Virameteekul, Chaewon Shin, Siegfried S Hirczy, Anat Mirelman, Ruth B Schneider, Joaquin A Vizcarra, Mariana H G Monje, Martina Mancini, Alice Nieuwboer, Margherita Fabbri, Ralf Reilmann, Alberto J Espay, Andrea Pilotto, Roongroj Bhidayasiri

Förderung

  • NICHD NIH HHS

Zitieren

APA

Virameteekul, S., Shin, C., Hirczy, S. S., Sarva, H., Paul, S. S., Maetzler, W., Mirelman, A., Schneider, R. B., Hausdorff, J. M., Vizcarra, J. A., Klucken, J., Monje, M. H. G., Mancini, M., Bonato, P., Nieuwboer, A., Horak, F. B., Rochester, L., Sanchez-Ferro, A., Zatti, C., …, & MDS Technology Study Group (2026). Assessing Digital Health Technologies for Outcome Measurement in Parkinson's Disease Drug Trials: A Systematic Review. Movement Disorders, 41(1), 40-62. https://doi.org/10.1002/mds.70097

Vancouver

Virameteekul S, Shin C, Hirczy SS, Sarva H, Paul SS, Maetzler W, et al. Assessing Digital Health Technologies for Outcome Measurement in Parkinson's Disease Drug Trials: A Systematic Review. Movement Disorders. 2026;41(1):40-62. doi:10.1002/mds.70097

BibTeX
@article{Virameteekul2026,
  author = {Virameteekul, Sasivimol and Shin, Chaewon and Hirczy, Siegfried S and Sarva, Harini and Paul, Serene S and Maetzler, Walter and Mirelman, Anat and Schneider, Ruth B and Hausdorff, Jeffrey M and Vizcarra, Joaquin A and Klucken, Jochen and Monje, Mariana H G and Mancini, Martina and Bonato, Paolo and Nieuwboer, Alice and Horak, Fay B and Rochester, Lynn and Sanchez-Ferro, Alvaro and Zatti, Cinzia and Fabbri, Margherita and Mestre, Tiago A and Reilmann, Ralf and Espay, Alberto J and Bloem, Bastiaan R and Pilotto, Andrea and Bhidayasiri, Roongroj and MDS Technology Study Group, MDS Technology Study Group},
  title = {Assessing Digital Health Technologies for Outcome Measurement in Parkinson's Disease Drug Trials: A Systematic Review},
  journal = {Movement Disorders},
  year = {2026},
  volume = {41},
  number = {1},
  pages = {40--62},
  doi = {10.1002/mds.70097}
}
Kostenlos starten →